Assessment of Risks for Renal Dysfunction: An Approach towards Light to Moderate Drinking and Therapeutic Doses of Acetaminophen | Chapter 20 | Current Practice in Medical Science Vol. 1

This study examined the kidney's response to therapeutic doses of acetaminophen (APAP) and light-to-moderate alcohol use while controlling for conditions including hypertension, diabetes, and obesity that might increase the kidney's susceptibility to APAP and/or alcohol toxicity. The study was a secondary data analysis of the 2003–2004 National Health and Nutrition Examination Survey (NHANES). Odds ratios (OR) and 95 percent confidence intervals (CI) were generated from multiple logistic regression models by further controlling for potential predisposing factors like namel to compare the likelihood that people who ingested therapeutic doses of APAP and light–moderate amounts of alcohol, compared to those who did not, would have kidney dysfunction. Even after controlling for hypertension, diabetes, and obesity, respondents who reported using therapeutic doses of APAP and light-to-moderate amounts of alcohol had statistically significant higher odds of developing renal dysfunction [OR(95 percent CI) = 1.64(1.28-2.10) self-report, 2.18(1.81-2.63) SCr, 4.60(3.03-7.00) BUN, 3.14(2.42-4.07) GFR, and 1.71(1.36-2.14) ALBCR]. On the kidney, APAP and alcohol were thought to have harmful effects. Unknown threshold dosages exist at which these effects start to manifest. The results of this study indicate that even therapeutic dosages of APAP and light to moderate amounts of alcohol may have negative health effects when drunk together. Given that many individuals may be exposed to both APAP and alcohol, this study brings to light a crucial public health issue. The findings could have an impact on health policy. We also investigated the possible effects of conditions that may make the kidney more vulnerable to APAP and/or alcohol toxicity, such as hypertension, diabetes, and obesity.

Author(s) Details:

Harrison Ndetan,

Department of Epidemiology and Biostatistics, School of Community and Rural Health, University of Texas Health Science Center, 11937 US Hwy 271, Tyler, TX 75708, United States of America.

Marion W. Evans Jr,

Department of Food Science, Nutrition, and Health Promotion, 105 Herzer Building, Box 9805, Mississippi State, MS 39762, United States of America.

Ashwani K. Singal,

Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama Birmingham, 1720 2nd Ave, South, BDB 380, Birmingham, AL 35294-0012, United States of America.

Lane J. Brunner,

Ben and Maytee Fisch College of Pharmacy, University of Texas, Tyler, 3900 University Blvd, Tyler, TX 75799, United States of America.

Kirk Calhoun,

University of Texas Health Science Center, 11937 US Hwy 271, Tyler, TX 75708, United States of America.

Karan P. Singh,

Department of Epidemiology and Biostatistics, School of Community and Rural Health, University of Texas Health Science Center, 11937 US Hwy 271, Tyler, TX 75708, United States of America.

George Einstein,

University of Science, Arts and Technology (USAT), Olveston, Montserrat.

Orien Tulp,

University of Science, Arts and Technology (USAT), Olveston, Montserrat.

Please see the link here: https://stm.bookpi.org/CPMS-V1/article/view/7339